Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Satoshi IkedaAkimasa SekineTomohisa BabaTakuma KatanoErina TabataRyota ShintaniShinko SadoyamaHideaki YamakawaTsuneyuki OdaRyo OkudaHideya KitamuraTae IwasawaTamiko TakemuraTakashi OguraPublished in: BMC pulmonary medicine (2019)
A high incidence of early termination of nintedanib was noted when patients were switched from pirfenidone. Anorexia and weight loss during prior pirfenidone administration may increase the rate of the early termination of subsequent nintedanib treatment.
Keyphrases
- idiopathic pulmonary fibrosis
- weight loss
- interstitial lung disease
- bariatric surgery
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- roux en y gastric bypass
- type diabetes
- risk factors
- gastric bypass
- combination therapy
- metabolic syndrome
- rheumatoid arthritis
- patient reported outcomes
- replacement therapy